“…Papers were included if they reported histological follow up of women diagnosed with endometrial hyperplasia and treated with a LNG‐IUS. After excluding one paper 15 which appeared to be an earlier report of a study that was later reported in full, 7 one that was second report 9 from the same study population 16 and one that reported on the effects of Progestasert®, a 65‐µg releasing device no longer available, and used unspecified criteria for histologic diagnosis, 17 we identified nine studies 7,8,10–14,16,18 and three case reports 19–21 that met the criteria for inclusion. There were no randomised controlled trials of a LNG‐IUS used for the treatment of endometrial hyperplasia.…”